AUA Annual Meeting

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Brock O'Neil, MD, physician, instructor in urologic surgery, Vanderbilt University, discusses a study that demonstrated evidence of superior quality of life after robotic assisted radical prostatectomy.

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.

Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.

Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).

Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.

Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.

Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule

A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.

E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.

Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.

Testicular self-examination remains highly cost-effective despite a negative recommendation from the United States Preventive Services Task Force (USPSTF), a cost-utility analysis suggested.

When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.

Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.

In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.

Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.

Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.

Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.